Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial.

ABSTRACT:

Introduction

Older adults are subject to higher COVID-19 infection and mortality rates. Safety and immunogenicity of MVC-COV1901, a protein subunit vaccine have been demonstrated in phase 2 clinical trial for the general population, and negative correlations have been observed between immune responses and age, however, older adults were under-represented.

Methods

A double-blind, randomized, multi-center study compared safety and immunogenicity of high-dose (25 mcg) to mid-dose (15 mcg) of MVC-COV1901 administered 2 times 28 days apart in 420 participants of 65 years and older. The results have been stratified by the comorbidity status.

Results

Both high and mid-dose regimens elicited mostly mild adverse events and robust immune responses when measured as neutralizing

SUBMITTER: Waits A 

PROVIDER: S-EPMC9422336 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature